Arizona Ketamine Treatment and Research Institute

Name

Arizona Ketamine Treatment and Research Institute

Website

https://arizonaketamine.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Arizona-based clinical practice and research entity providing ketamine-based treatments, suggested by its name; no operational, financial, or leadership details are available because the company website is inaccessible due to a DNS resolution error.

Ownership category

akta.pro rank

Product category

Ketamine Treatment Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro industry

PRIMARYHLAIACAC

Neurology & CNS Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAKAIAE

Headache & Migraine Medicine

Healthcare & Life Sciences/Specialist Medical Practice/Neurology

Keywords

• Ketamine treatment
• Clinical research services
• Infusion therapy
• Mental health treatment
• Pain management

Headquarters

HQ city

Tempe

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations

Core offering

Based solely on the company name, the organization appears to provide ketamine-based clinical treatment to patients and conduct associated research. No specific treatment protocols, service modalities, conditions treated, or research programs are documented because the company website is inaccessible due to a Cloudflare DNS resolution error.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Compass Pathways: Clinical-stage psychedelic medicine company developing psilocybin therapy for treatment-resistant depression, with an established clinical-research infrastructure. Comparable to AKTRI's research-institute positioning, though Compass is publicly traded, drug-development focused, and operates at substantially greater scale.
• Janssen Pharmaceuticals (Spravato): Manufacturer of Spravato (esketamine), the FDA-approved nasal spray for treatment-resistant depression. Comparable patient indication and treatment setting (REM-certified outpatient clinics), and represents the dominant reimbursed competitor in the clinic-administered antidepressant space.
• MindMed: Clinical-stage psychedelic and CNS therapeutics company with a research pipeline across LSD, MDMA, and DMT. Adjacent peer given shared patient population (mental health) and research-driven business model, though MindMed is pharma-focused rather than clinic-operating.
• Better U (formerly Delic Holdings): Operator of ketamine clinics under the 'Ketamine Wellness Centers' brand alongside broader psychedelic wellness assets. Comparable in clinic-level operating model while providing a read on multi-site scaling and corporate-level execution.

Direct peers

• Nue Life: Ketamine therapy provider combining in-clinic infusions with telehealth and digital mental-health support. Comparable to AKTRI in the ketamine treatment modality and patient population, with a stronger technology and digital wraparound layer.
• Mindbloom: A leading U.S. ketamine therapy provider offering at-home and remote-guided ketamine treatments for depression, anxiety, and PTSD. Comparable to AKTRI in clinical indication, drug (ketamine), and patient demographic, though it operates a digital/telehealth model rather than a single-site infusion clinic.
• Field Trip Health (Stella): Operated ketamine-assisted psychotherapy clinics across North America before restructuring. Closely comparable as a clinic-based ketamine provider with a research/data arm, offering direct read-across on unit economics, patient throughput, and clinic-model scalability.
• Klarity Clinic: Multi-state ketamine infusion clinic focused on depression, PTSD, and chronic pain. Directly comparable service line, drug protocol, and outpatient specialty-clinic delivery model to AKTRI.

Regional players

• Cedar Psychiatry: Multi-specialty psychiatry and ketamine infusion practice serving Arizona and other Southwestern markets. Directly comparable regional peer with overlapping geography, offering the cleanest read on Phoenix-area patient demand and reimbursement dynamics.

Emerging players

• Wave Neuroscience: Neuroscience-focused clinic operator offering ketamine infusions and MEProc/neurofeedback protocols for PTSD and TBI. Comparable outpatient specialty-clinic model with overlapping indications (PTSD, depression), though differentiated by its neurofeedback technology stack.

Market position

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arizona Ketamine Treatment and Research Institute